THE IMPORTANCE OF BIOMARKERS IN THE EARLY DETECTION OF CANCER

Аннотация

Cancer remains one of the leading causes of mortality worldwide, and early detection plays a crucial role in improving patient survival rates. Traditional diagnostic methods, such as imaging and histopathology, often detect cancer only after it has advanced, reducing treatment effectiveness. Biomarkers—biological molecules found in blood, body fluids, or tissues—offer a promising alternative for early diagnosis. They can indicate abnormal cellular processes or tumor formation before clinical symptoms appear. Advances in molecular biology and genomics have led to the identification of numerous biomarkers that enable early screening, precise diagnosis, and monitoring of therapeutic responses. Malignant neoplasms continue to pose a significant global health burden, with rising incidence and mortality rates. Delayed identification often results in limited therapeutic options and poor prognoses. Conventional diagnostic approaches, including radiological imaging, histological examination, and physical assessment, frequently detect tumors only at advanced stages. In this context, molecular biomarkers have emerged as essential tools for early recognition of oncological disorders. These indicators, detectable in biological specimens such as blood, urine, or tissue, reflect underlying pathological changes before clinical manifestations become evident. Recent technological progress in genomics, proteomics, and metabolomics has enabled the discovery of novel molecular signatures, facilitating precision screening and personalized intervention strategies. Identification of specific biomarkers allows clinicians to stratify patients according to risk, monitor disease progression, and evaluate therapeutic efficacy in real time.